Effects of Platelet Mimicking Nanoparticles in Patients With Cirrhosis
A legfontosabb adatok
- Ki végzi
- Assistance Publique - Hôpitaux de Paris
- Hol
- Franciaország1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Résztvevők
- 60 fő vett részt
- Kezdés
- 2024. ápr. 25.
- Befejezés
- 2025. jan. 28.
- A vizsgálat típusa
- Megfigyeléses, 2 csoport
- A vizsgált kezelések
- Additional blood sampling at the same time and in addition of samplings already done for the patient's standard of care.
- A regiszteradat frissítve
- 2026. április 23.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Részt vehetnek
A regiszter feltételei, szó szerint
Mind a 11 feltétel megnézéseKevesebb
Ki vehet részt
- Adult patients who are beneficiaries of a social security scheme or beneficiaries entitled to it
- Patients followed for a cirrhotic pathology at the Paul Brousse hospital and benefiting from a scheduled anaesthesia consultation for a scheduled interventional or surgical procedure
- For non-cirrhotic patients: adult patients who are beneficiaries of a social security scheme or beneficiaries entitled to it, benefiting from a blood test scheduled as part of their usual preoperative care (patients in the hepatology or digestive surgery department operated on at the Paul Brousse hospital)
Ki nem vehet részt
- Patient on long-term antiplatelet or anticoagulant therapy
- Patient who has taken a non-steroidal anti-inflammatory drug within 5 days prior to the blood test
- Patient on estrogenic therapy
- Patient on immunosuppressive or immunomodulatory therapy
- Patient with cancer under treatment or treated in the last 6 months
- Patient not wishing to participate in the study
- Patient with a known haemostasis abnormality other than cirrhosis
- Patients with thrombopathy of genetic origin
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Haemostasis of cirrhotic patients is disturbed at different levels: primary haemostasis, coagulation and fibrinolysis, leading to a new haemostatic balance. Thrombocytopenia and thrombopathy are counterbalanced by elevation of Von Willebrand factor (VWF) and diminution of ADAMTS13 activity. Exploration of primary haemostasis is difficult in the laboratory, and non-interpretable in case of thrombocytopenia. Moreover, these tests are not performed under flow conditions. The T-TAS®01 system analyses the total haemostatic capacity in whole blood under shear stress, with chips coated with type 1 collagen. Platelets transfusion performs poorly in cirrhotic patients and is not recommended before invasive procedure. Platelets mimicking nanoparticles (PMNs) have been developed by Pr Sen Gupta (Case Western Reserve University, Cleveland, Ohio (OH), USA). PMNs have been proven to collaborate with platelets and enhance haemostasis in different shear conditions in vitro and in different models of haemorrhage in vivo. The assumption of this study is that the perfusions characteristics of cirrhotic patients in the T-TAS®01 system will be different from those of non-cirrhotic patients, and that platelets mimicking nanoparticles will improve these characteristics.
A vizsgálat 2 csoportja
- Cirrhotic patients
Patients known to have a cirrhosis, with an invasive procedure scheduled at the Paul Brousse hospital
Kezelés: Additional blood sampling at the same time and in addition of samplings already done for the patient's standard of care.
- Non-cirrhotic patients
Patients without cirrhosis, with an invasive procedure scheduled at the Paul Brousse hospital
Kezelés: Additional blood sampling at the same time and in addition of samplings already done for the patient's standard of care.
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Exploration of Primary Haemostasis in Cirrhotic Patients With T-TAS System and Effects of Platelets Mimicking Nanoparticles
- A regiszteradat frissítve
- 2026. április 23.